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 Introduction 
 The role of innate immunity in kidney transplantation 
has been overlooked for years, but now it is generally ac-
cepted that it represents the first step in rejection mecha-
nisms and guides the development of adaptive immune 
response. Its role was elucidated by Janeway  [1] in 1989, 
who postulated that non-self-recognition is initiated by a 
number of germ-line encoded receptors named pattern 
recognition receptors (PRRs). According to this model, 
PRRs recognize a repertoire of bacterial or viral mole-
cules, called pathogen-associated molecular patterns 
(PAMPs), such as lipopolysaccharide and peptidoglycan. 
PAMPs recognition by PRRs leads to the production of 
several pro-inflammatory mediators that are essential in 
the first phase of inflammation and guides the subsequent 
development of adaptive immune response. However, 
this model could not explain the innate immunity activa-
tion in autoimmune diseases and allotransplantation, as-
suming that it is performed under sterile conditions. It 
was to the merit of Dr. Polly Matzinger in the nineties to 
clarify how innate immunity can also be activated by non-
infectious stimuli. She expanded Janeway’s hypothesis 
postulating that PRRs recognize as danger signals also self 
molecules that are released from dying or necrotic cells, 
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 Abstract 
 For a long time now, kidney transplant rejection has been 
considered the consequence of either cellular or antibody-
mediated reaction as a part of adaptive immunity response. 
The role of innate immunity, on the other hand, had been 
unclear for many years and was thought to be only ancillary. 
There is now consistent evidence that innate immune re-
sponse is a condition necessary to activate the machinery of 
rejection. In this setting, the communication between anti-
gen-presenting cells and T lymphocytes is of major impor-
tance. Indeed, T cells are unable to cause rejection if innate 
immunity is not activated. This field is currently being ex-
plored and several experiments in animal models have 
proved that blocking innate immunity activation can pro-
mote tolerance of the graft instead of rejection. The aim of 
this review is to systematically describe all the steps of innate 
immunity response in kidney transplant rejection, from anti-
gen recognition to T-cells activation, with a focus on clinical 
consequences and possible future perspectives. 
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the so-called damage/danger-associated molecular pat-
terns (DAMPs)  [2] . According to this model, every injury 
to the graft leads to the production of DAMPs that poten-
tially engage PRRs. Recently, Matzinger  [3] noticed that 
Dr. Walter Land was the first to foresee the danger mod-
el before the publication of her theory  [4] , when he found 
out that a single shot of superoxide dismutase, a free rad-
ical scavenger, could reduce the long-term rate of rejec-
tion episodes in kidney transplant patients  [5] . The aim 
of this review is to systematically describe all the steps of 
innate immunity response in kidney transplant rejection, 
from antigen recognition to T-cells activation. Finally, fu-
ture perspectives based on experimental models will be 
discussed.
 Overview of Innate-Adaptive Immunity Interplay 
 The communication between innate and adaptive im-
munity mainly relies on antigen presentation. The role of 
antigen-presenting cells (APCs) may be played by B cells, 
γδ T-cells, macrophages and perhaps natural killer (NK) 
cell  [6] . However, in most cases, the cells presenting the 
antigen to immune competent lymphocytes are dendritic 
cells (DCs), which provide stronger activation signals 
than other cells. Before presenting the antigen, DCs need 
to change from immature cells specialized for antigen 
capture into mature cells that activate T lymphocytes. 
This phenotypic transition relies on the presence of an 
inflammatory micro-environment and represents an es-
sential prerequisite for T cells activation. The quiescent 
DCs, indeed, release chemokines and cytokines that favor 
Treg differentiation  [7] . When DAMPs and/or PAMPs 
are present instead, mature DCs can efficiently activate 
naïve T cells. This happens in lymph nodes, where T cells 
are attracted by DCs-released chemokines. Naïve T cells 
require 3 signals to be activated and avoid death and/or 
tolerance. The first signal is provided by the contact be-
tween the alloantigen presented by APCs and the specific 
receptor located on the surface of T cells. However, this is 
an anergic/apoptotic signal. A second signal (costimula-
tion) is needed to rescue T cells from apoptosis and to 
activate them. This is given by the contact between pro-
teins located on the APCs, such as CD80 and CD86 of the 
B7 family, and CD28 on the surface of T cells. Also im-
portant is the contact between CD40 and its ligand CD40L 
also called CD 154. On the other side, some other recep-
tors on T cells, such as cytotoxic T lymphocyte antigen 4 
(CTLA-4) and programmed death 1, engage B7 proteins 
and inhibit proliferation. CTLA-4 has a higher affinity for 
B7 receptors on APCs, up to 100 times higher than CD28. 
When APCs have not been activated by DAMPs or 
PAMPs, they express low levels of CD80 and CD86. 
CTLA-4, due to its higher affinity, prevents CD28 en-
gagement by the B7 family and, thus, impairs T-cell acti-
vation  [8] . On the other side, when APCs are activated by 
noxious stimuli, B7 receptors increase on DCs and be-
come available for CD28 engagement and T-cell activa-
tion. This is a good example of how the inflammatory 
milieu (i.e. the balance between stimulatory and inhibi-
tory costimulatory molecules) can decide the T-cell des-
tiny ( fig. 1 ). Furthermore, a third signal is also needed to 
guide T-helper cells differentiation  [9] . This is given by 
some cytokines, such as interleukin (IL)-12, IL-23 and 
TGF-beta, which regulate the differentiation of Th sub-
sets  [10] .
 Who Recognized the Danger? The Role of PRRs 
 Therefore, the initiation of allo-response in renal 
transplantation needs DAMPs recognition by PRRs of 
the innate immunity. This enables APCs maturation 
and subsequent activation of the adaptive immune 
 response, as discussed previously. But how can the dan-
ger be perceived? Innate immunity can rely on a wide 
array of cellular and soluble receptors to carry out this 
task.
 Cellular Receptors 
 The most studied and better characterized cellular re-
ceptors are toll-like receptors (TLRs), NOD-like recep-
tors (NLRs) and RIG-I-like receptors, while soluble me-
diators include complement and pentraxins. TLRs are 
integral membrane glycoproteins located either on the 
external surface of the cell membrane or on the endo-
somes and are expressed on DCs, macrophages, B cells, 
NK cells, endothelial cells and many other cells  [11] . To 
date, human functional TLRs are divided into 2 sub-
groups, depending on their localization: TLR1, TLR2, 
TLR4, TLR5, TLR6 and TLR11 are expressed on cell sur-
faces and recognize mainly microbial membrane com-
ponents, while TLR3, TLR7, TLR8 and TLR9 are ex-
pressed only in intracellular vesicles and recognize mi-
crobial nucleic acids. Different intracellular pathways of 
signal transduction have been described for these 2 
groups of receptors. TLRs expressed on cells surface, 
upon antigen binding, dimerize and transduce the in-
flammatory signal through the intracellular toll/IL-1 re-
ceptor (TIR) domain. TIR dimerization on the cytoplas-
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mic side of plasma membrane recruits adapter proteins, 
such as myeloid differentiation primary response gene 
88 (MyD88) and MyD88-adapter, in turn activate intra-
cellular kinases responsible for signal transduction, in-
cluding IL-1 receptor associated kinases (IRAK)  [12] , 
IκB kinases, and protein kinase C  [13] . This results in the 
translocation of transcription factors into the nucleus, 
such as AP-1 and nuclear factor kappa-light-chain-en-
hancer of activated B cells (NF-κB)  [14] , where they ac-
tivate the transcription of pro-inflammatory genes, in-
cluding cytokines, chemokines, adhesion and costimula-
tory molecules ( fig. 2 ).
 On the other hand, TLRs located on the intracellular 
vesicles, when engaged by viral moieties, initiate a signal-
ing cascade that leads to the transcription of type I inter-
ferons through the translocation of the interferon re-
sponse factors (IRFs) into the nucleus, such as IRF3 
( fig. 2 ).
 NLRs are intracellular sensors that collaborate with 
TLRs in recognizing PAMPs and DAMPs in order to ac-
tivate NF-κB and MAP kinases  [15] . These receptors are 
expressed in the epithelial tubular cells and seemed to be 
crucially involved in the inflammatory response triggered 
by IRI in a murine model  [16] . NOD leucine-rich repeat 
and pyrin domain containing protein (NLRPs), including 
NLRP3, are a distinct subfamily of NLRs that, following 
activation by PAMPs or DAMPs, oligomerize and recruit 
both the adaptor protein ASC and the inactive form of 
protease caspase-1 to form a multimolecular complex 
termed inflammasome that has proteolytic properties 
 Fig. 1. When DCs have not been activated by noxious stimuli (left), 
they express low levels of B7 proteins (such as CD80, CD86). Some 
receptors on T cells, such as CTLA-4, prevent CD28 engagement 
by the proteins of B7 family, due to their higher affinity. This 
avoids inappropriate T-cell activation and proliferation when an 
inflammatory medium is absent. On the other side (right), when 
DAMPs engage PRRs such as TLRs, the expression of CD80 and 
CD86 (B7) increases notably on the surface of DCs. This allows the 
engagement of CD28 by B7 proteins, thus providing the necessary 
co-stimulation that T cells need to proliferate upon antigen recog-
nition. For a more detailed description, see the text. TCR = T cell 
receptor; PD-1 = programmed death 1; Ag = antigen; T = T cell. 
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and is essential to activate by cleavage some proinflam-
matory cytokines, such as IL-1β and IL-18 ( fig. 2 )  [17] .
 Finally, RIG-I-like receptors are intracellular receptors 
that intercept and recognize the intracellular viral replica-
tion through the direct interaction with the dsRNA pro-
duced by viral RNA to form the genome  [18] .
 For readers who are particularly interested to know 
more on this subject, some excellent reviews have been 
recently published about the role of PRRs in general  [19] 
and, more specifically, in kidney diseases  [20] .
 Soluble Receptors 
 Besides the cellular arm, the innate immunity also 
comprises humoral components, namely complement 
and pentraxins.
 The complement system includes more than 30 pro-
teins both in plasma and on cell surfaces and presents 3 
distinct activation cascades, the classical, alternative and 
mannose-binding lectin pathway  [21] . Although the 
complement system plays important protective roles 
against infection and tumors, it can be harmful to the 
 Fig. 2. TLRs engagement with either PAMPs or DAMPs activates 
an intracellular cascade of kinases that leads to the production of 
transcription factors, such as AP1, NF-κB and IRF3, which regu-
late the transcription of many inflammatory genes. TLRs expressed 
on the cell surface, upon antigen binding, dimerize and transduce 
the inflammatory signal through the intracellular TIR domain. 
TIR dimerization on the cytoplasmic side of plasma membrane 
recruits adapter proteins, such as MyD88 (also known as TIRAP) 
and MyD88-adapter like (Mal), which in turn activate intracellular 
kinases responsible for signal transduction, including IRAK, 
MAP-kinases, IKKs, and protein kinase C. NLRP3 activation fol-
lowing DAMPs sensing builds up a multimolecular complex called 
inflammasome that, through caspase-1, cleaves and activates some 
pro-inflammatory cytokines, such as IL-1 and IL-18, into the ac-
tive form. AP1 = Activation protein-1; IKK = IκB kinase; In-cas-
pase = inactive caspase; MAP3K = MAP3 kinase; TAK1 = TGFβ 
activated kinase 1; TBK = TANK binding kinase; TIRAP = TIR 
domain containing adaptor protein; TRAM = TRIF-related adap-
tor molecule; TRAF6 = TNF receptor-associated factor 6; TRIF = 
TIR-domain-containing adapter-inducing interferon-β. 
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graft through activation of both inflammatory response 
and coagulation cascade  [22] . A number of events includ-
ing brain death of the donor, IRI, infection, coagulation, 
and any type of tissue damage can trigger systemic and 
renal activation of complement in this setting. Curiously, 
the lectin pathway seems to be the most commonly in-
volved during IRI. This happens because the mannose-
binding lectin can bind some oligosaccharides other than 
mannose that are expressed by necrotic and late apop-
totic cells  [23] . Locally produced C5a and C3a are critical 
for the activation of adaptive immunity, since they enable 
the necessary costimulation that T cells need to prolifer-
ate upon engagement with APCs.
 Pentraxins are a family of multimeric pattern-recogni-
tion proteins that can be divided into short pentraxins 
and long pentraxins  [24] . Short pentraxins, that is, C-re-
active protein and serum amyloid P-component, are op-
sonins produced in the liver in response to proinflamma-
tory cytokines, such as IL-6 and contribute to innate im-
munity responses. The prototypic long pentraxin is 
pentraxin 3 (PTX3), a fluid phase pattern recognition 
molecule that is produced by DCs and macrophages in 
response to TLRs and inflammatory cytokines. PTX3 has 
antibody-like properties and binds C1q activating the 
complement cascade  [25] . Moreover, it is expressed by 
renal proximal tubular cells  [26] . Its role in renal trans-
plantation remains elusive at the moment: whether it ex-
erts beneficial or harmful effects is still unclear  [27, 28] .
 What Is Recognized? The Essential Role of DAMPs 
 DAMPs include all the substances that are released 
from damaged tissues and that can be recognized by the 
specific receptors of innate immunity (PRRs). A large 
number of DAMPs released by damaged or necrotic cells 
has been identified so far and several functional experi-
ments in animal models have confirmed their essential 
role in the development of rejection. DAMPs can be 
broadly classified into those that are actively expressed or 
secreted by damaged cells and those that are passively re-
leased by dying cells. DCs, lymphocytes, inflammasomes 
and IgM antibodies can recognize them. Moreover, dam-
aged extracellular proteins, such as fragments of hyaluro-
nan, heparin sulphate, fibronectin and biglycan, can act 
as efficient DAMPs  [29] . One of the most studied proteins 
is the high-mobility group box 1 (HMGB1) protein, 
whose role is to regulate chromosomal stability. It is shed 
from dying or damaged cells in the extracellular matrix, 
where it has chemotactic effects for virtually all immune 
cells and activates APCs through engagement with TLR2, 
TLR4 and the receptor for advanced glycation end 
(RAGE) products  [30] . Heat shock proteins (HSPs) are a 
family of intracellular chaperones involved in folding and 
unfolding of newly synthetized polypeptides. In stress 
conditions, such as hypoxia, their production and secre-
tion are enhanced and leads to APCs’ activation through 
TLRs engagement  [31] . HSP70 expression is already in-
creased in kidneys removed from deceased donors; this 
precedes a more dramatic upregulation when reperfusion 
later occurs  [32] . Leakage of ATP (extracellular ATP) and 
uric acid out of damaged cells can activate the inflamma-
some, leading to the production of IL-1β and IL-18. In 
particular, extracellular ATP induces P2X8-dependent 
pores formation on cell membranes by the assembly of 
pannexin-1 hemichannels. This allows the entry of extra-
cellular ATP itself and other extracellular DAMPs into 
the cells, where they can engage NLRP3 in order to acti-
vate the inflammasome  [29] . Coagulation proteases, be-
sides generating fibrin, are involved in the inflammation 
process through engagement of the so-called protease-
activated receptors on endothelial cells, DCs and T cells. 
These receptors are activated upon cleavage by the coagu-
lation proteases and increase the expression of adhesion 
molecules and promote the alloantigen-primed T-cell re-
cruitment  [33] .
 Innate Immunity Activation in Kidney 
Allotransplantation 
 A number of factors may activate innate immunity in 
allotransplantation. In the brain-deceased donor, the in-
tracranial hypertension triggers a massive release of cyto-
kines and growth factors with consequent activation of 
cell-adhesion molecules and leukocyte infiltration in the 
kidney  [34] . Another consequence of brain death is local 
upregulation and the activation of complement that can 
contribute to create an inflammatory environment  [35] . 
The manipulation of the kidney during removal may also 
produce mechanical injury. However, the most danger-
ous and best studied mechanism of graft damage is rep-
resented by IRI. Ischemia leads to poor ATP generation 
and intracellular acidosis through the activation of the 
glycolytic pathway. This deranges the activity of sodium/
potassium ATPase pumps and disrupts the osmotic equi-
librium. As a result, cells swell due to the osmotic stress 
and start to express adhesion molecules, such as P-selec-
tin, E-selectin and ICAM-1, that will promote leukocytes 
infiltration of the graft in the reperfusion phase. The re-
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perfusion phase leads to the production of a huge quan-
tity of reactive oxygen species (ROS). In the first minutes 
after reperfusion, ROS production is thought to originate 
from endothelial cells that have been damaged by the pre-
vious phase of ischemia. The mitochondrial electron 
transport chain is the system mostly involved in ROS pro-
duction. Leakage of electrons from damaged mitochon-
dria generates superoxide anions, hydrogen peroxide, hy-
droxyl radicals, hypochlorous acid and singlet oxygen. 
Afterwards, a second burst of ROS production is due to 
neutrophils migration to the graft, where they contribute 
to tissue damage and promote the subsequent recruit-
ment of alloreactive T cells  [36] .
 Oxidative and genotoxic stress determine cellular 
damage that often result in regulated forms of necrosis, 
which may involve mediators such as serine/threonine 
protein kinase RIP1-RIP3 (necroptosis) or glutathione 
peroxidise 4 (ferroptosis)  [37, 38] . These types of necrosis 
may potentially lead to massive release of intracellular 
DAMPS.
 It is worthy to consider that inflammation does not 
only drive tissue injury but also favors its repair. TLR2 
activation by DAMPs engagement determines clonal ex-
pansion and activation of renal progenitor cells located 
along the thick limbs of the renal tubule, a process that 
leads to hastened regeneration. In addition, following 
TLR4 activation, the release of IL-22 by macrophages and 
DCs activates a specific receptor on these tubular cells 
that favors the reparative process. Selective blockade of 
TLR signalling in the recovery phase of IRI leads to a con-
sistent delay in epithelial regeneration  [39, 40] . Failure to 
resolve acute inflammation following injury can lead to 
the development of chronic inflammation that contrib-
utes to the pathogenesis of graft dysfunction  [41] . DAMPs 
themselves may indeed affect renal fibrosis, an aberrant 
process, which tends to re-establish tissue homeostasis 
through deposition of extracellular matrix. The DAMPs-
mediated activation of fibroblasts, pericytes and mesan-
gial cells leads to fibrosis via the induction of molecular 
pathways that result in TGF-β signalling and epithelial-
mesenchymal transition of these cells  [42] .
 Timely regulation of inflammation and recovery, both 
active processes, is subjected to a wide array of factors, in 
which innate immunity mediators play a consistent role. 
Recently, increasing attention has been paid to the influ-
ence of macrophage phenotype in the different phases of 
ischemia-reperfusion injury. Classically activated M1 
macrophages are considered proinflammatory cells, 
which enter the site of injury along neutrophils following 
the release of chemokines (such as CX3CL1, released by 
renal endothelial cells). Neutrophils apoptosis and their 
subsequent phagocytosis switch macrophages towards an 
anti-inflammatory phenotype (M2, alternatively activat-
ed) that contributes to inflammation resolution and pro-
motes healing  [43] . A consistent number of mediators are 
implied in this phenotypic switch: genetic or pharmaco-
logical inhibition of macrophage colony stimulating fac-
tor 1 (CSF-1), which is released by damaged renal epithe-
lial cells, resulted in a reduction of M2 polarization and 
impaired recovery  [44] . Of note, CSF-1 also acts on renal 
tubular cells themselves via a specific receptor, which is 
upregulated upon injury. This signalling results in de-
creased apoptosis, increased proliferation and lessened 
interstitial fibrosis  [45] . Similarly, genetic depletion of 
IRAK-M, a macrophage-specific inhibitor of TLR and IL-
1β signalling induced after their activation, resulted in 
interstitial accumulation of M1 macrophages with subse-
quent interstitial fibrosis and tubular atrophy  [46] .
 If IRI represents the major early event that triggers in-
nate immunity, it should be pointed out that every injury 
to the graft – including infection, drug toxicity, tissue 
damage – may theoretically lead to the production of 
PAMPs or DAMPs with consequent activation of the in-
nate immunity. Of particular importance, pathogen- or 
allograft-derived antigens can activate innate immunity 
response and create a pro-inflammatory milieu. Some T 
cells specific for microbial peptides presented by self-ma-
jor histocompatibility complex (MHC) molecules can 
cross-react with allogeneic MHC, while bacterial supe-
rantigens can directly activate large populations of T cells. 
Therefore, infections experienced before transplantation 
can give rise to memory alloreactive T cells that may be 
more resistant to immunosuppression than naïve T cells 
 [47] . Infections occurring late after transplantation may, 
in theory, elicit pro-inflammatory signals that activate 
tolerant T cells by enabling their escape from immuno-
suppression and/or peripheral mechanisms of tolerance, 
thereby precipitating rejection  [48] . Activation of innate 
immunity by trivial triggers could explain the occurrence 
of some cases of unexpected late deterioration of renal 
function in patients with stable transplants. Depending 
on the balance between effector and regulatory T cells, 
these events may result in innocent renal function fluc-
tuations or progression to irreversible renal failure. Re-
cent emphasis has been given to the complex interplay 
between gut microbiota and innate and adaptive immu-
nity. For instance, in an animal model of IRI-induced 
AKI, germ-free mice had worse structural and functional 
outcomes compared to mice that were colonized with 
wild-type gut flora. Authors suggested that a more pro-
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nounced T helper 1 phenotype in germ-free mice could 
have promoted a worse injury  [49] .
 It is known that fecal microbiota undergoes dramatic 
changes after kidney transplantation, resulting in the 
overgrowth of some bacterial species and overall reduc-
tion in microbial diversity. The resulting changes in gut 
microbiota have been associated with the development of 
post-transplant diarrhoea and Enterococcus-related in-
fectious complications. Moreover, patients with acute re-
jection have substantial different gut microbial composi-
tion  [50] . Whether microbiota has an active role in acute 
rejection mechanisms is a fascinating hypothesis that de-
serves further validation. Indeed, changes in gut micro-
biota may represent only the consequence of immuno-
suppression and antibiotic prophylaxis given to trans-
plant patients  [51] . However, its role cannot be 
undervalued since drug metabolism can be affected by 
changes in gut flora, as Lee et al.  [52] recently demon-
strated that Faecalibacterium prausnitzii abundance in 
the first week after transplantation had an impact on ta-
crolimus dose requirements.
 Antigen Presentation and Activation of Adaptive 
Immunity 
 After antigen uptake, phenotypic transition and mi-
gration to lymphoid tissues, DCs can finally present the 
antigen to immunocompetent cells. In kidney transplan-
tation, antigen presentation to T cells has 3 different mo-
dalities: (i) direct presentation: the donor’s DCs present 
directly the antigen to T cells (ii); indirect presentation: 
recipient’s DCs intercept the antigen, become mature, 
and present the antigen to T cells; (iii) semi-direct presen-
tation: recipient’s DCs take up membrane fragments of 
donor’s DCs membranes for presentation through indi-
rect pathway  [53] . Once T lymphocyte has been activated, 
there is a large influx of Ca 2+ ions into the cytoplasm lead-
ing to the activation of calcineurin, a phosphatase that 
dephosphorylates a family of proteins called nuclear-fac-
tor of activated T cells (NFAT). After dephosphorylation, 
NFAT can enter the nucleus and stimulates the synthesis 
of IL-2, a potent pro-proliferative cytokine that expands 
the T clone itself and strengthens the adaptive response 
against the allo-antigen presented. The contact with 
APCs also activates the mitogen-activated protein kinase 
and the protein kinase C-NF-κB pathways. This results in 
the activation of IL-2, IL-2 receptor, NF-κB, and a further 
activation of APCs  [54] . The ligand of IL-2 to its receptor 
(CD25), together with IL-15, activates a kinase, called Ja-
nus kinase 3, and delivers growth signals through the 
family of phosphoinositide-3 kinase (PI3-K) which, to-
gether with a protein-kinase B (AKT), activates a cascade 
of other kinases that provide the signals for cell prolifera-
tion  [55] . The downstream effector of PI3-K is the mam-
malian target of rapamycin (mTOR), which regulates cell 
growth and proliferation ( fig. 2 ,  3 ). mTOR phosphory-
lates the 40S ribosomal 6 kinase and cyclin-dependent ki-
nases, providing the transduction of proliferative signals 
to T cells  [56] . After receiving all these signals, activated 
T lymphocytes require the synthesis of nucleotides to 
proliferate. Under the regulation of IL-12 released from 
macrophages, CD4+ T lymphocytes differentiate into 
Th1 and Th17 subsets  [57] . Furthermore, CD4+ cells can 
also activate B cells and induce their differentiation into 
memory and plasma cells  [58] .
 Future Approaches 
 In addition to operative protection of the graft, several 
of the innate immunity pathways described above may 
theoretically be exploited to induce tolerance instead of 
rejection. Possible ways to inhibit innate immunity acti-
vation include PRRs and DAMPs antagonism and co-
stimulation blockade.
 Among PRRs, TLRs and their adapter molecules, such 
as MyD88 and TIR-domain-containing adapter-induc-
ing interferon-β, are the best studied so far. TLR2 and 
TLR4 are upregulated following ischemia or nephrotoxic 
drugs playing a pro-inflammatory role  [59] that may be 
prevented in mice with genetic deficiency of these recep-
tors or treated with TLR2-antisense  [60] . MyD88 defi-
ciency is associated with an altered balance of Tregs over 
Th17 cells that promotes tolerance  [61] , although graft 
rejection can occur independently of MyD88  [62] . Even 
in humans, the importance of the TLRs machinery in 
generating alloimmune response has been highlighted. 
Krüger et al.  [63] demonstrated that donor kidneys bear-
ing a nonsense mutation of TLR-4 had an increased rate 
of immediate graft function along with a reduced expres-
sion of some inflammatory mediators at renal biopsy, 
such as TNF-alpha and MCP-1, whose messenger RNA 
(mRNA) was found to be significantly reduced compared 
to patients bearing the wild-type gene. Following these 
observations, increasing attention has been directed to-
wards the development of compounds able to modulate 
TLR signalling. For instance, OPN-305, the first human-
ized IgG4 monoclonal antibody against TLR2 has been 
tested in a phase I randomized, double-blind, placebo-
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controlled study on healthy subjects. The drug complete-
ly blocked TLR2 receptor on monocytes, was well toler-
ated and apparently produced no major adverse reactions 
 [64] . A clinical trial evaluating OPN-305 on renal trans-
plant recipients to prevent delayed graft function is cur-
rently ongoing (NCT01794663). Some negative regula-
tors of the TLRs may also constitute a potential therapeu-
tic target in the future. For instance, IRAK-M activates a 
negative feedback that alters IRAK1- and IRAK4-depen-
dent signal transduction  [14] . IRF-4, unlike other IRFs, 
suppresses TLRs signaling by binding to MyD88 and its 
lack aggravates IRI in kidneys  [65] . Toll-IL-1R8 (TIR8), 
a  negative regulator of TLR/IL-1R, dampens IRI and 
Tir8(–/–) mice have increased TNF-alpha and IL-6 secre-
tion from DCs and worse renal graft outcome  [66] .
 Regarding DAMPs, several strategies have been based 
on HMGB-1 inhibition using molecules that compete 
with its receptors, such as TLR4 and RAGE. The discov-
ery of a TLR4 cysteine residue critical for HMGB1 bind-
ing may favor selective inhibition of this DAMP  [67] . In 
murine models, mice treated with anti-HMGB1 antibod-
ies at the time of transplantation have less tubulointersti-
tial infiltration by neutrophils and macrophages and re-
duced apoptosis of tubular epithelial cells  [68] . As an al-
ternative, encouraging results have been obtained with 
direct HMGB1-targeting, leading to the identification of 
 Fig. 3. T cells that are activated by an efficient antigen presentation 
by DCs increase their cytoplasmic calcium concentration through 
the opening of calcium channels. The increase in cytoplasmic Ca 2+ 
activates calcineurin, a phosphatase that dephosphorylates NFAT. 
This allows the entry of NFAT into the nucleus, in which it acti-
vates the transcription of IL-2, a potent pro-proliferative cytokine. 
The pro-proliferative signal of IL-2 is further mediated by the JAK/
STAT pathway and by the PI3-K pathway, with the latter that ac-
tivates mTOR, an essential kinase that regulates cell growth and 
proliferation. JAK3 = Janus kinase 3; PDK1 = phosphoinositide-
dependent kinase-1; Rheb  = Ras homolog enriched in brain; 
STAT = signal transducer and activator of transcription; TSC1/2 = 
tuberous sclerosis 1/2. 
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compounds that directly bind HMGB1, ranging from 
small natural or synthetic molecules, such as glycyrrhizin 
and gabexate mesilate, to HMGB1-specific antibodies, 
peptides, proteins as well as bent DNA-based duplexes 
 [69] .
 Beyond the inhibition of danger recognition (i.e. the 
PRRs-DAMPs interplay), T-cell activation by DCs may 
be altered in order to induce tolerance. This may be ac-
complished by blocking costimulation, the signal that 
rescues T cells from apoptosis and leads to clonal expan-
sion. In this field, one of the best studied molecules is 
CTLA-4, which prevents CD80-CD86 engagement to 
CD28 due to its higher affinity to the ligand. Several strat-
egies proved to be efficient in preventing kidney trans-
plant rejection in mouse and non-human primates mod-
els, from the use of recombinant CTLA4-Ig to the em-
ployment of monoclonal antibodies directed against 
CD40, CD28 and CD86  [70] .
 Further attempts to prevent innate immunity activa-
tion by IRI may be based on the inhibition of caspase-1, 
inflammasome, complement and NF-κB. In 2006, Gilm-
ore and Herscovitch  [71] counted 785 inhibitors of NF-κB 
including anti-oxidant products, proteasomes and prote-
asome-inhibitors, I-κB phosphorylation and degradation 
inhibitors, and other aspecific ones. Some of these inhibi-
tors have been used in oncology and inflammatory dis-
eases, but compounds designed as specific NF-κB inhibi-
tors are not yet clinically available for kidney transplanta-
tion. Other possible targets may be represented by 
micro-RNAs, a class of small endogenous non-coding 
RNAs that regulate gene expression through the transla-
tional control of mRNAs. They have recently emerged as 
key regulators of TLR-signalling pathways, and new tech-
nologies for the identification and manipulation of miR-
NA expression in vivo are now available  [72] . Of course, 
the knowledge of innate immunity pathways remains in-
completely understood and every new discovery in the 
field seems to challenge the old beliefs. For example, it has 
been recently demonstrated that innate sensing of alloge-
neic non-self can occur without the presence of DAMPs 
through monocytes-derived DCs  [73] . Moreover, it should 
be highlighted that the clinical scenario is really different 
from clean facilities and sterile laboratories: humans are 
exposed to an assortment of pathogens and other environ-
ment perturbations that nullify most of the attempts to 
selectively block a specific signalling pathway. Therefore, 
the redundancy of the system may justify why the success 
observed in targeting innate immunity pathways in ani-
mal models has not been confirmed in humans yet.
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